FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416703896> ?p ?o ?g. }

• W2416703896 abstract "Abstract Cytokines play an important role in activating the immune system against malignant cells. One of these cytokines, interleukin-4 (IL-4) has entered clinical phase I trials because of its immunoregulatory potency. In the present study we report that recombinant human (rh) IL- 4 has major direct antiproliferative effects on one human lung cancer cell line (CCL 185) in vitro as measured by a human tumor cloning assay (HTCA), tritiated thymidine uptake, and counting cell numbers and marginal activity in a second cell line (HTB 56) in the HTCA. This activity could be abolished by neutralizing antibody against rhIL-4. The biological response of the tumor cells to the cytokine is correlated with expression of receptors for human IL-4 on both the mRNA level and the protein level. The responsive cell line, CCL 185, secretes IL-6 after being incubated with rhIL-4. On the other hand, neutralizing antibodies against IL-6 showed no influence on the growth modulatory efficacy of rhIL-4 in this cell line. Furthermore, CCL 185 does not show detectable production of IL-1, tumor necrosis factor alpha or interferon gamma after incubation with rhIL-4. Thus, the response to rhIL-4 is not mediated through autocrine production of these cytokines triggered by rhIL-4. In a next series of experiments some of the cell lines were xenotransplanted to BALB/c nu/nu mice. Subsequently, the mice were treated for 12 days with two doses of 0.5 mg/m2 rhIL-4 or control vehicle subcutaneously per day. Treatment with rhIL-4 yielded a significant inhibition of tumor growth versus control in two of the non-small cell lung cancer cell lines being responsive in vitro (CCL 185, HTB 56). Histology of the tumors in both groups showed no marked infiltration of the tumors with murine hematopoietic and lymphocytic cells consistent with the species specificity of IL-4. In contrast, no tumor growth inhibition was found in the small cell lung cancer cell lines (HTB 119, HTB 120) being nonresponsive in vitro. We conclude that rhIL-4 has direct antiproliferative effects on the growth of some human non-small cell lung cancer cell lines in vitro and in vivo, which together with its regulatory effects on various effector cell populations makes this cytokine an interesting candidate for further investigation in experimental cancer treatment." @default.
• W2416703896 created "2016-06-24" @default.
• W2416703896 creator A5001209793 @default.
• W2416703896 creator A5014793533 @default.
• W2416703896 creator A5038151568 @default.
• W2416703896 creator A5042046015 @default.
• W2416703896 creator A5042721449 @default.
• W2416703896 creator A5044425723 @default.
• W2416703896 creator A5044565481 @default.
• W2416703896 creator A5047844249 @default.
• W2416703896 creator A5071498213 @default.
• W2416703896 creator A5075328050 @default.
• W2416703896 date "1993-11-01" @default.
• W2416703896 modified "2023-09-30" @default.
• W2416703896 title "Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo" @default.
• W2416703896 cites W1480773154 @default.
• W2416703896 cites W1498092139 @default.
• W2416703896 cites W1512413304 @default.
• W2416703896 cites W1517067629 @default.
• W2416703896 cites W1553221858 @default.
• W2416703896 cites W1578348197 @default.
• W2416703896 cites W1601600505 @default.
• W2416703896 cites W1635113498 @default.
• W2416703896 cites W191322575 @default.
• W2416703896 cites W1916368909 @default.
• W2416703896 cites W1918737925 @default.
• W2416703896 cites W1936856060 @default.
• W2416703896 cites W1966644054 @default.
• W2416703896 cites W1984404339 @default.
• W2416703896 cites W2013538974 @default.
• W2416703896 cites W2016806826 @default.
• W2416703896 cites W2018385931 @default.
• W2416703896 cites W2024833436 @default.
• W2416703896 cites W2046555621 @default.
• W2416703896 cites W2068626888 @default.
• W2416703896 cites W2074445204 @default.
• W2416703896 cites W2091691801 @default.
• W2416703896 cites W2093489766 @default.
• W2416703896 cites W2095433933 @default.
• W2416703896 cites W2112826159 @default.
• W2416703896 cites W2118267493 @default.
• W2416703896 cites W2118641357 @default.
• W2416703896 cites W2124314287 @default.
• W2416703896 cites W2134828784 @default.
• W2416703896 cites W2139775011 @default.
• W2416703896 cites W2140612321 @default.
• W2416703896 cites W2144885158 @default.
• W2416703896 cites W2144942357 @default.
• W2416703896 cites W2164015588 @default.
• W2416703896 cites W2170300105 @default.
• W2416703896 cites W2407008956 @default.
• W2416703896 cites W2415588222 @default.
• W2416703896 cites W340792320 @default.
• W2416703896 doi "https://doi.org/10.1182/blood.v82.9.2837.2837" @default.
• W2416703896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8219232" @default.
• W2416703896 hasPublicationYear "1993" @default.
• W2416703896 type Work @default.
• W2416703896 sameAs 2416703896 @default.
• W2416703896 citedByCount "56" @default.
• W2416703896 countsByYear W24167038962013 @default.
• W2416703896 countsByYear W24167038962014 @default.
• W2416703896 countsByYear W24167038962016 @default.
• W2416703896 countsByYear W24167038962018 @default.
• W2416703896 countsByYear W24167038962020 @default.
• W2416703896 crossrefType "journal-article" @default.
• W2416703896 hasAuthorship W2416703896A5001209793 @default.
• W2416703896 hasAuthorship W2416703896A5014793533 @default.
• W2416703896 hasAuthorship W2416703896A5038151568 @default.
• W2416703896 hasAuthorship W2416703896A5042046015 @default.
• W2416703896 hasAuthorship W2416703896A5042721449 @default.
• W2416703896 hasAuthorship W2416703896A5044425723 @default.
• W2416703896 hasAuthorship W2416703896A5044565481 @default.
• W2416703896 hasAuthorship W2416703896A5047844249 @default.
• W2416703896 hasAuthorship W2416703896A5071498213 @default.
• W2416703896 hasAuthorship W2416703896A5075328050 @default.
• W2416703896 hasBestOaLocation W24167038961 @default.
• W2416703896 hasConcept C128240485 @default.
• W2416703896 hasConcept C150903083 @default.
• W2416703896 hasConcept C153911025 @default.
• W2416703896 hasConcept C159654299 @default.
• W2416703896 hasConcept C17991360 @default.
• W2416703896 hasConcept C203014093 @default.
• W2416703896 hasConcept C207001950 @default.
• W2416703896 hasConcept C2777371288 @default.
• W2416703896 hasConcept C2778690821 @default.
• W2416703896 hasConcept C2779261636 @default.
• W2416703896 hasConcept C54355233 @default.
• W2416703896 hasConcept C81885089 @default.
• W2416703896 hasConcept C86803240 @default.
• W2416703896 hasConcept C8891405 @default.
• W2416703896 hasConceptScore W2416703896C128240485 @default.
• W2416703896 hasConceptScore W2416703896C150903083 @default.
• W2416703896 hasConceptScore W2416703896C153911025 @default.
• W2416703896 hasConceptScore W2416703896C159654299 @default.
• W2416703896 hasConceptScore W2416703896C17991360 @default.
• W2416703896 hasConceptScore W2416703896C203014093 @default.
• W2416703896 hasConceptScore W2416703896C207001950 @default.
• W2416703896 hasConceptScore W2416703896C2777371288 @default.
• W2416703896 hasConceptScore W2416703896C2778690821 @default.
• W2416703896 hasConceptScore W2416703896C2779261636 @default.

• next